THE EFFICACY OF THERAPY AT DOSES SUGGESTED FOR
SELF-AID AGAINST GD POISONING (U)

by

J.A. Lipp

PROJECT NO. 13030

April 1979

This document has been approved
for public release and sale; its
distribution is unlimited.
THE EFFICACY OF THERAPY AT DOSES SUGGESTED FOR SELF-AID AGAINST GD POISONING

by

D.A. Lipp

PROJECT NO. 13030

UNCLASSIFIED
THE EFFICACY OF THERAPY AT DOSES SUGGESTED FOR SELF-AID AGAINST GD POISONING (U)

by

J.A. Lipp

ABSTRACT

Monkeys were exposed to 1 LD₅₀ of GD and treated with a combination of clonazepam, atropine and toxogonin at doses suggested for self-aid. The doses used were based on equivalent human doses of 2 mg/man of atropine, 5 mg/man of clonazepam and 280 mg/man of toxogonin. This therapy, given by intramuscular injection when the initial signs of poisoning occurred, adequately suppressed the abnormal EEG and muscular activity. Atropine reversed cardiac arrhythmia, but the GD-induced respiratory depression and bradycardia appeared more resistant and in some animals additional atropine was necessary. Control animals that only received therapy did not appear to be incapacitated. The results of this study suggest that this therapy would produce a degree of protection against GD poisoning and could be used as self-aid.
UNCLASSIFIED

DEFENCE RESEARCH ESTABLISHMENT SUFFIELD
RALSTON ALBERTA

SUFFIELD TECHNICAL PAPER NO. 497

THE EFFICACY OF THERAPY AT DOSES SUGGESTED FOR
SELF-AID AGAINST GD POISONING (U)

by

J.A. Lipp

INTRODUCTION

It has been reported that the drug combination of clonazepam
and atropine is an effective therapy for GD poisoning (1,2). The mini-
mal effective dose was 0.07 mg/kg of clonazepam and 0.25 mg/kg of atro-
pine (2). The side effects of a drug must be considered when determining
the dose to be used in a therapeutic regime; however, circumstances
dictate the severity of side effects that can be tolerated. Thus, the
dose used to treat an individual exposed to GD must be sufficient to
counteract the fatal effects even though the side effects of the drugs
may be debilitating; whereas the dose of therapy used in only suspected
cases of exposure to GD should not induce intolerable side effects. The
dose used in previous studies (2) would possibly induce some debilitation
(especially the dose of atropine) and should not be used in cases of only
suspected poisoning.

The object of this study is to determine if a dose of clona-
zepam and atropine can be used which will not induce incompatible side
effects yet produce a degree of protection against GD poisoning. It was decided to use atropine at a dose of 0.03 mg/kg which is equivalent to 2 mg per 70 kg/man, the usual clinical dose, and clonazepam at 0.07 mg/kg which is equivalent to 5 mg per 80 kg/man. Previous studies have reported that this dose of clonazepam is effective; however, the effectiveness of the proposed dose of atropine is unknown.

PROCEDURE

The procedure used in this study has been described in detail in previous studies (1,2). Briefly, nine monkeys with chronic implanted cerebral electrodes were used. Control EEG, respiratory and heart rates were obtained. EEG, respiratory and heart rate recordings began immediately following the injection of GD and continued throughout the experiment. GD was diluted with 0.9% saline and injected into the thigh of the monkey at a dose of 7 - 8 μg/kg. When the animal began to exhibit the initial signs of GD poisoning which include oral movements, peripheral tremor and synchronization of the EEG pattern, therapy which consisted of clonazepam (0.07 mg/kg), atropine (0.03 mg/kg), and toxogonin (4.0 mg/kg) was administered by IV injection into the brachial vein. Additional atropine was given to any animal that exhibited severe dyspnea after receiving the initial therapy. All animals were placed in their respective holding cages within 2 hours of receiving GD and observed for the remainder of the day.

Three monkeys were given the therapy without receiving GD and the above mentioned physiological activity recorded.

RESULTS

All animals exposed to GD exhibited some symptoms of poisoning, which included changes in the EEG pattern (Fig. 1-B, 2-B), alterations in the respiratory pattern (Fig. 2-B) and changes in cardiac activity (Fig. 1-B) or apnea. It should be noted that the dose of GD used in this study was about 1 LD₅₀.

Following administration of therapy, the animals appeared alert,
but quiet, exhibiting no abnormal movements. The EEG exhibited desynchronised sharp wave activity characteristic of clonazepam (Fig. 1-D, 2-C). The cardiac arrhythmia exhibited by one monkey immediately disappeared (Fig. 1-C) and respiration became synchronous (Fig. 1-D, 2-D).

The heart rate in all animals showed a significant decrease while the respiratory rate increased. Two monkeys had to be given additional atropine and they continued to exhibit dyspnea and bradycardia (Fig. 3-D). Within one hour of receiving GD, the average heart rate had decreased 59% while respirations had increased 49% (Fig. 4).

All animals were lethargic and exhibited some ataxia when placed in the holding cages, but were capable of maintaining an upright posture within one hour.

The control animals, that received therapy only, did not exhibit any significant changes in behavior or EEG activity. One exhibited a small decrease in heart rate (20%) which occurred within five minutes of receiving the drugs.

**DISCUSSION**

The results of this experiment showed that the dose of therapy used in this study provided some protection to animals exposed to 1 LD$_{50}$ of GD. The effectiveness of clonazepam in suppressing seizure activity and abnormal movements had been confirmed in other studies. The peripheral effects of atropine were more evident than the central action. Administration of atropine immediately reversed the cardiac arrhythmia, whereas the GD-induced respiratory depression remained evident and some animals required additional atropine. Consequently the dose of atropine (2 mg/70 kg) could be considered as the minimal effective dose and any reduction in the dose would possibly negate the efficacy of atropine.

Administration of therapy to control animals did not appear to affect their normal behavior which may indicate that an equivalent dose may not interfere with the normal function of a human. This should be
confirmed by human clinical trial.

Therefore, the results of this study suggest that therapy consisting of atropine (2 mg/70 kg), clonazepam (5 mg/70 kg) and toxogonin (280 mg/70 kg) would produce a degree of protection against GD poisoning yet not interfere with the normal behavior, and may be considered for self-aid. This therapeutic regimen would probably be effective against limited exposure to GD and beneficial as an initial treatment for severe exposure. In addition, if the therapy were given as a prophylaxis and no exposure occurred, it should not produce any debilitating effects and the person should be able to perform the required duties.
BIBLIOGRAPHY


Figure 1: Effect of GD and therapy upon EEG, heart and respiratory rate of the monkey.

(A) Control. H.R. = 260/min; resp = 32/min.
(B) 15 min post GD. H.R. = 170; resp = 36.
(C) Immediately following administration of therapy. H.R. = 280; resp = 48.
(D) 5 min post therapy. H.R. = 280; resp = 48.
(E) 30 min post therapy. H.R. = 230; resp = 48.
(F) 1 hr post therapy. H.R. = 200; resp = 52.

Lt. Fr.-Par. Cx = Left Frontal-parietal cortex.
H.R. = Heart rate.
Figure 2: EEG, heart rate and respiratory rate following exposure to GD and therapy in the monkey.

(A) Control. H.R. = 220/min; resp = 32/min.
(B) 10 min post GD. H.R. = 220; resp 50.
(C) Immediately following administration of therapy. H.R. = 260; resp = 56.
(D) 15 min post therapy. H.R. = 250; resp = 56.
(E) 30 min post therapy. H.R. = 120; resp = 56.
(F) 1 hr post therapy. H.R. = 210; resp = 72.
Figure 3: Cerebral electrical activity, heart rate and respiratory rate following exposure to GD and therapy.

(A) Control. H.R. = 240/min; resp 36/min.
(B) 10 min post GD. H.R. = 220; resp = 36.
(C) 5 min post therapy. H.R. = 230; resp = 40.
(D) 15 min post therapy. H.R. = 190; resp = 40. Monkey given additional atropine.
(E) 30 min post therapy. H.R. = 160; resp = 36.
(F) 1 hr post therapy. H.R. = 160; resp = 38.
Figure 4: Graph of Heart Rate and Respiratory Activity Following Exposure to 90 and Therapy.
Monkeys were exposed to 1 LD$_{50}$ of GD and treated with a combination of clonazepam, atropine and toxogonin at doses suggested for self-aid. The doses used were based on equivalent human doses of 2 mg/man of atropine, 5 mg/man of clonazepam and 280 mg/man of toxogonin. This therapy, given by intramuscular injection when the initial signs of poisoning occurred, adequately suppressed the abnormal EEG and muscular activity. Atropine reversed cardiac arrhythmia, but the GD-induced respiratory depression and bradycardia appeared more resistant and in some animals additional atropine was necessary. Control animals that only received therapy did not appear to be incapacitated. The results of this study suggest that this therapy would produce a degree of protection against GD poisoning and could be used as self-aid.

(U)
### KEY WORDS

<table>
<thead>
<tr>
<th>GD</th>
<th>Clonazepam</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atropine</td>
</tr>
<tr>
<td></td>
<td>Toxogonin</td>
</tr>
<tr>
<td></td>
<td>Seizure Activity</td>
</tr>
<tr>
<td></td>
<td>Convulsions</td>
</tr>
<tr>
<td></td>
<td>Heart Rate</td>
</tr>
<tr>
<td></td>
<td>Respiratory Activity</td>
</tr>
</tbody>
</table>

### INSTRUCTIONS

1. **ORIGINATING ACTIVITY**: Enter the name and address of the organization issuing the document.

2a. **DOCUMENT SECURITY CLASSIFICATION**: Enter the overall security classification of the document including special warning terms whenever applicable.

2b. **GROUP**: Enter security reclassification group number. The three groups are defined in Appendix 10 of the DAS Security Regulations.

3. **DOCUMENT TITLE**: Enter the complete document title in all capital letters. Titles in all cases should be unclassified. If a sufficiently descriptive title cannot be selected without classification, show title classification with the usual one-capital-letter abbreviation in parentheses immediately following the title.

4. **DESCRIPTIVE NOTES**: Enter the category of document, e.g., technical report, technical note or technical letter. If appropriate, enter the type of document, e.g., interim, progress, summary, annual or final. Give the inclusive dates when a specific reporting period is covered.

5. **AUTHOR(S)**: Enter the name(s) of author(s) as shown on or in the document. Enter last name, first name, middle initial. If military, show rank. The name of the principal author is an absolute minimum requirement.

6. **DOCUMENT DATE**: Enter the date (month, year) of Establishment approval for publication of the document.

7a. **TOTAL NUMBER OF PAGES**: The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.

7b. **NUMBER OF REFERENCES**: Enter the total number of references cited in the document.

8a. **PROJECT OR GRANT NUMBER**: If appropriate, enter the applicable research and development project or grant number under which the document was written.

8b. **CONTRACT NUMBER**: If appropriate, enter the applicable number under which the document was written.

8c. **ORIGINATOR'S DOCUMENT NUMBER(S)**: Enter the official document number by which the document will be identified and controlled by the originating activity. This number must be unique to this document.

9b. **OTHER DOCUMENT NUMBER(S)**: If the document has been assigned any other document numbers (either by the originator or by the sponsor), also enter this number(s).

10. **DISTRIBUTION STATEMENT**: Enter any limitations on further dissemination of the document, other than those imposed by security classification, using standard statements such as:

   (1) "Qualified requesters may obtain copies of this document from their defense documentation center."

   (2) "Announcement and dissemination of this document is not authorized without prior approval from originating activity."

11. **SUPPLEMENTARY NOTES**: Use for additional explanatory notes.

12. **SPONSORING ACTIVITY**: Enter the name of the departmental project office or laboratory sponsoring the research and development. Include address.

13. **ABSTRACT**: Enter an abstract giving a brief and factual summary of the document, even though it may also appear elsewhere in the body of the document itself. It is highly desirable that the abstract of classified documents be unclassified. Each paragraph of the abstract shall end with an indication of the security classification of the information in the paragraph (unless the document itself is unclassified) represented as (TS), (SI), (CI), (RI), or (L).

   The length of the abstract should be limited to 30 single-spaced standard typewritten lines. 740 words long.

14. **KEY WORDS**: Key words are technically meaningful terms or short phrases that characterize a document and could be helpful in cataloging the document. Key words should be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code, name, geographic location, may be used as key words but will be followed by an indication of technical context.